Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relmacabtagene Autoleucel as 2nd-Line in Aggressive B-Cell NHL
NCT06093841Phase 2Active, not recruiting
- Sponsor
- Shanghai Ming Ju Biotechnology
- Start
- Nov 2023
- Primary completion
- Jan 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of relmacabtagene autoleucel in B-cell non-Hodgkin lymphoma, sponsored by Shanghai Ming Ju Biotechnology. Started Nov 2023; status: active, not recruiting.
02
Drugs
relmacabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06093841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06093841.